Technical Description
The invention relates to the synthesis of calcium lactate nanostructures (CaLNSs) designed for efficient siRNA delivery in RNA interference (RNAi) therapeutics and drug delivery. These nanostructures serve as stable, biocompatible carriers for targeted gene silencing and combination cancer therapy applications.
Problems Addressed
- Lacks Stable SiRNA Delivery
- Inefficient Cellular Uptake
- Poor Endosomal Escape
- High Production Cost
- Toxic Biological Vectors
- Limited Therapeutic Efficiency
Tech Features
- Enhanced siRNA Delivery
- Efficient Gene Silencing
- Better Biocompatibility
- Improved Drug Solubility
- Affordable Manufacturing Process
- Enhanced Therapeutic Efficiency
Target Audience
- Biotechnology Research Companies
- Pharmaceutical and Therapeutics Industries
- Nanomedicine & Drug Delivery Firms
- Biomedical Device & Material Developer
- Research & Development
Tech ID: P06-1725 TRL 6 Patent Status: Granted Available For Exclusive and Non-exclusive License
